A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion

Conditions: Immunoglobulin Light Chain (AL) Amyloidosis Interventions: Drug: ABBV-383 Sponsors: AbbVie Not yet recruiting

Source: ClinicalTrials.gov - December 6, 2023 Category: Research Source Type: clinical trials